Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Flufenamic Acid→

Flufenamic Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
530-78-9
Molecular formula
C14H10F3NO2
Molecular weight
281.23 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)fenamate derivative
Mechanism of action
Inhibits cyclo-oxygenase-mediated prostaglandin synthesis, reducing inflammatory mediators and producing analgesic and anti-inflammatory effects.
Indications / reported uses
  • Historically used for short-term treatment of pain and inflammatory conditions, including dysmenorrhoea and musculoskeletal pain, in countries where flufenamic acid remains authorised; current availability and safety restrictions vary

Sources: NLM MeSH — Flufenamic acid · PubMed — Flufenamic acid NSAID pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Flufenamic Acid Environmental Risk Assessment (ERA) (the Flufenamic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.